A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland

References

• Hindryckx P, Vande Casteele N, Novak G, et al. The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug[s] for our patients? J Crohns Colitis. 2018;12(1):105–119.
   PubMed Web of Science ®Google Scholar
• Danese S, Bonovas S, Peyrin-Biroulet L. Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice. J Crohns Colitis. 2017;11(10):1258–1266.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–1960.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: Three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease. J Crohns Colitis. 2020;14(1):23–32.
   PubMed Web of Science ®Google Scholar
• stelara-epar-product-information_en.pdf. [cited 2020 Dec 7]. https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf.
   Google Scholar
• Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, et al. Ustekinumab for Crohn's disease: results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis. 2020;14(1):33–45.
   PubMed Web of Science ®Google Scholar
• Eberl A, Hallinen T, Af Björkesten C-G, et al. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE) ). Scand J Gastroenterol. 2019;54(6):718–725.
   PubMed Web of Science ®Google Scholar
• Liefferinckx C, Verstockt B, Gils A, et al. Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biologic therapies: a national cohort study. J Crohns Colitis. 2019;13(11):1401–1409.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Krisam J, Wehling C, et al. Ustekinumab: “real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease. World J Gastroenterol. 2019;25(31):4481–4492.
   PubMed Web of Science ®Google Scholar
• Iborra M, Beltrán B, Fernández-Clotet A, et al. Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2020;52(6):1017–1030.
   PubMed Web of Science ®Google Scholar
• Ollech JE, Normatov I, Peleg N, et al. Effectiveness of ustekinumab dose escalation in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2021;19(1) :104–110.
   PubMed Web of Science ®Google Scholar
• Bar-Gil Shitrit A, Ben-Ya’acov A, Siterman M, et al. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn’s disease: a multicenter Israeli study. United European Gastroenterol J. 2020;8(4):418–424.
   PubMed Web of Science ®Google Scholar
• Harris RJ, McDonnell M, Young D, et al. Early real-world effectiveness of ustekinumab for Crohn's disease. Frontline Gastroenterol. 2020;11(2):111–116.
   PubMed Web of Science ®Google Scholar
• Bots S, Gecse K, Barclay M, et al. Combination Immunosuppression in IBD. Inflamm Bowel Dis. 2018;24(3):539–545.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Marano C, et al. Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(10):2244–2255.e9.
   PubMed Web of Science ®Google Scholar
• Gómez Espín R, Nicolás De Prado I, Gil Candel M, et al. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn’s disease. A real life study. Rev Esp Enferm Di. 2021;113(2):110–115.
   PubMed Web of Science ®Google Scholar
• Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–512.
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet Lond Engl. 1980;315(8167):514.
   Google Scholar
• Af Björkesten C-G, Ilus T, Hallinen T, et al. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort. Eur J Gastroenterol Hepatol. 2020;32(12):1507–1513.
   PubMed Web of Science ®Google Scholar
• Samaan M, Campbell S, Cunningham G, et al. Biologic therapies for Crohn’s disease: optimising the old and maximising the new. F1000Res. 2019;8:1210.
   Google Scholar
• Sands B, Gasink C, Jacobstein D, et al. OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate-severe Crohn’s disease patients: results from IM-UNITI maintenance study. Gut. 2017;66(Suppl 2):A23.
   Google Scholar
• Haider SA, Yadav A, Perry C, et al. Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease. Therap Adv Gastroenterol. 2020;13:175628482095924.
   Web of Science ®Google Scholar
• Dalal RS, Njie C, Marcus J, et al. Predictors of ustekinumab failure in Crohn’s disease after dose intensification. Inflamm Bowel Dis. 2020. DOI:10.1093/ibd/izaa282
   Google Scholar
• Fumery M, Peyrin-Biroulet L, Nancey S, et al. Effectiveness and safety of ustekinumab intensification at 90 mg every four weeks in Crohn’s disease: a multicenter study. J Crohns Colitis. 2021;15(2):222–227.
   Web of Science ®Google Scholar
• Kopylov U, Hanzel J, Liefferinckx C, et al. Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy . Aliment Pharmacol Ther. 2020;52(1):135–142.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–834.
   PubMed Web of Science ®Google Scholar
• Mitrev N, Vande Casteele N, Seow CH, et al. Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11–12):1037–1053.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(9):1655–1668.e3.
   PubMed Web of Science ®Google Scholar
• Verstockt B, Dreesen E, Noman M, et al. Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates. J Crohns Colitis. 2019;13(7):864–872.
   PubMed Web of Science ®Google Scholar
• Soufflet N, Boschetti G, Roblin X, et al. Concentrations of ustekinumab during induction therapy associate with remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2019;17(12):2610–2612.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease. Gastroenterology. 2018;154(6):1660–1671.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48(1):65–77.
   PubMed Web of Science ®Google Scholar
• Painchart C, Brabant S, Duveau N, et al. Ustekinumab serum trough levels may identify suboptimal responders to ustekinumab in Crohn's disease. Dig Dis Sci. 2020;65(5):1445–1452.
   PubMed Web of Science ®Google Scholar
• Battat R, Kopylov U, Bessissow T, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017;15(9):1427–1434.e2.
   PubMed Web of Science ®Google Scholar
• Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–1427.
   PubMed Web of Science ®Google Scholar
• Restellini S, Khanna R, Afif W. Therapeutic drug monitoring with ustekinumab and vedolizumab in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(10):2165–2172.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Kramer BC, Gasink C, et al. P680 Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years. J Crohns Colitis. 2019;13(Supplement_1):S459–S460.
   Web of Science ®Google Scholar
• Axelrad JE, Roy A, Lawlor G, et al. Thiopurines and inflammatory bowel disease: current evidence and a historical perspective. World J Gastroenterol. 2016;22(46):10103–10117.
   PubMed Web of Science ®Google Scholar
• Bourrier A, Carrat F, Colombel J-F, et al. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther. 2016;43(2):252–261.
   PubMed Web of Science ®Google Scholar